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Although the role of interleukin-2 (IL-2) and interferon gamma (gIFN)
is still poorly understood in hyperthyroid diseases, it is reasonable to
assume that these cytokines may be present at higher levels in Graves
disease (GD) than in other primarily non-autoimmune thyroid dis-
eases. In order to look for an easy method to distinguish GD from
primarily non-autoimmune causes of hyperthyroidism, we compared
13 healthy individuals with 21 treated and untreated hyperthyroid GD
patients and with 19 patients with hyperthyroidism due to other
etiologies: 7 cases of multinodular goiter, 5 cases of excessive hor-
mone replacement and 7 cases of amiodarone-associated hyperthy-
roidism. All patients presented low TSH levels and a dubious clinical
thyroid state. We found a good correlation between TSH and serum
IL-2 levels (r = 0.56; P<0.01). Serum IL-2 (P<0.01) and gIFN (P<0.01)
levels were lower in the hyperthyroid group of patients than in control
subjects, suggesting a depressed TH1 pattern in the T-cell subset of
hyperthyroid patients. GD had normal IL-2 levels, while patients with
other forms of thyrotoxicosis presented decreased IL-2 levels (P<0.05).
There was no difference between treated and untreated GD patients.
We suggest that the direct measurement of serum IL-2 level may help
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Since cytokines have a pivotal role in the
generation and perpetuation of immune and
inflammatory responses, it has been sug-
gested that these polypeptide mediators may
also be involved in the development and
perpetuation of autoimmune diseases (1).
However, their role in human thyroid physi-
ology and in hyperthyroid states is still poorly
understood. In Graves disease (GD) a pleth-
ora of different cytokines are produced by
intrathyroid lymphocytes and also by folli-
cular thyroid cells (2,3). There are some
indications that this cytokine production may
be altered (4,5). A disturbed immune regula-
tion causing a dominance of TH2 cytokine
production has been postulated to be crucial
in the pathogenesis of the disease (6). Also,
serum cytokine levels seem to show a good
correlation with endocrine status, indicating
that they could even function as markers of
thyroid activation in GD (7). On the other
hand, it is difficult to evaluate the influence
of hyperthyroxinemia by itself, since anti-
thyroid drugs interfere with cytokine pro-
duction (8-10).
Our hospital receives many patients from
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iodine-deficient regions and many individu-
als taking amiodarone and other drugs that
cause a relatively high frequency of border-
line TSH levels (11). We do not perform
routine measurements of thyroid-stimulat-
ing antibodies, and the clinical signs and
symptoms of the patients are not always so
clear, especially in amiodarone-associated
hyperthyroid patients. Hence, it is not al-
ways easy to determine the cause of thyro-
toxicosis. In order to look for an easy method
to distinguish GD from other primarily non-
autoimmune thyroid diseases, we compared
GD with other conditions producing hyper-
thyroidism but considered not to have an
autoimmune primary etiology, including
multinodular goiter, excessive amounts of
thyroid hormone, amiodarone-induced hy-
perthyroidism, and with normal healthy con-
trol subjects. Our aim was to determine
whether cytokine concentration in blood se-
rum can distinguish GD from other non-
autoimmune states.
For this purpose, after approval by the
Medical Ethics Committee, we studied 13
healthy volunteers (6 males and 7 females;
median age, 24 years; range, 21-27 years) in
an initial investigation designed to provide
normal parameters for our cytokine assays.
Forty hyperthyroid outpatients whose hy-
perthyroid picture has been clinically diffi-
cult to appraise were enrolled in our study.
TSH and free T4 (fT4) measurements con-
firmed the diagnosis. Patients whose thyroid
antibody levels were higher than 500 IU/ml
were excluded from the study. After careful
clinical examination, a blood sample was
obtained from each subject for serum TSH,
fT4, anti-thyroglobulin (TgAb) and anti-per-
oxidase (TPOAb) antibody, interleukin-2 (IL-
2) and interferon gamma (gIFN) determina-
tions. All patients presented TSH levels be-
low the normal range. None of the patients or
controls had infectious diseases or other au-
toimmune diseases. Twenty-one subjects had
Graves disease whereas in the other 19
patients, hyperthyroidism was primarily at-
tributed to non-autoimmune diseases. The
patients were divided into the following
groups: group I - 21 patients (6 males and 15
females; median age, 34 years; range, 12 to
60 years) had a clinically well-established
diagnosis of Basedow-Graves disease. Eight
of these subjects were newly diagnosed, un-
treated hyperthyroid patients. The other 13,
although already on thionamide therapy, still
presented depressed TSH levels. Group II - 7
patients (1 male, 6 females; median age, 51
years; range, 42 to 72 years) with a recent
clinical diagnosis of multinodular goiter con-
firmed by ultrasonography and/or fine needle
aspiration cytology. No one was receiving
any treatment. Group III - 5 patients (2 males,
3 females; median age, 42 years; range, 18 to
62 years) with pituitary deficiency and using
excessive amounts of levothyroxine. Four of
these five patients had undergone surgery
for pituitary tumors and the fifth had a diag-
nosis of Sheehan disease. Group IV - 7 pa-
tients (1 male, 6 females; median age, 48
years; range, 42 to 65 years) with amiodar-
one-associated hyperthyroidism. These pa-
tients had received a median dose of 400 mg/
day of the antiarrythmic drug for four years
on average in order to control life-threaten-
ing cardiac arrhythmia. At the time of this
investigation, all were considered to be clini-
cally stable. No one showed any evidence of
any previous or concomitant thyroid disease
when submitted to clinical examination, ul-
trasonography and laboratory evaluation.
Blood samples were obtained between
9:00 and 13:00 h and the sera were kept
frozen at -25oC until the time for use. Cy-
tokine determinations were run using single
kits to increase test precision. TSH and fT4
were determined using fluometric enzyme
immunoassays (Baxter Diagnostic Inc.,
Deerfield, IL, USA). The TSH assay had a
minimal detectable dose of 0.05 U/l, with
normal values ranging from 0.38 to 6.15 U/l.
fT4 had a functional sensitivity of 0.2 ng/dl,
with normal values ranging from 0.74 to 2.1
ng/dl. Anti-thyroglobulin and anti-peroxi-
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dase antibodies were measured using immu-
noradiometric quantitative assays (Serono,
Rome, Italy); intra- and inter-assay variation
was 5 and 6%, respectively, with a sensitiv-
ity of 1.0 IU/ml for TPOAb. We considered
antibody values higher than 100 IU/ml to be
positive.
IL-2 and gIFN were measured using solid-
phase enzyme immunoassay kits (Genzyme
Diagnostics, Cambridge, MA, USA). Both
IL-2 and gIFN kits had a detection limit of
100 pg/ml and the intra- and inter-assay
coefficients of variation were 3.2 and 9.5%,
respectively, for IL-2 and 6.9 and 10.5%,
respectively, for gIFN.
Data are reported as means ± SEM. Since
the results did not show a normal distribu-
tion, they were analyzed by the Kruskal-
Wallis (H statistics), c2 or Wilcoxons rank
sum (Z statistics), as appropriate. Correla-
tions between different parameters were cal-
culated by linear regression (r statistics). The
level of significance was set at P<0.05. For
statistical purposes, undetectable cytokine
levels were assigned an arbitrary value cor-
responding to the lowest detectable amount
for each assay.
The hyperthyroid groups (I-IV) and the
control group were similar in terms of age
and sex (H and c2 = NS). No control subject
presented positive thyroid antibodies. The
mean values measured in the control groups
showed normal thyroid status (TSH = 1.94 ±
0.07 U/l and fT4 = 1.36 ± 0.42 ng/dl) and
cytokine parameters (IL-2 = 1501.53 ± 416.44
pg/dl and gIFN = 135.30 ± 37.52 pg/dl). In
the hyperthyroid groups, TSH levels were
0.04 ± 0.01, 0.05 ± 0.02, 0.13 ± 0.04, 0.09 ±
0.03 U/l, and fT4 levels were 3.94 ± 0.39,
2.86 ± 0.85, 1.96 ± 0.26, 1.70 ± 0.25 ng/dl
for groups I to IV. IL-2 and gIFN levels were
1671.57 ± 364.77 and 112.35 ± 24.51 pg/dl
for group I, 874.28 ± 330.44 and 129.01 ±
48.76 pg/dl for group II, 928.00 ± 415.01
and 90.66 ± 40.54 pg/dl for group III, and
416.00 ± 157.23 and 102.16 ± 38.62 pg/dl
for group IV, respectively.
There was a strong correlation between
serum TSH and IL-2 levels in all measure-
ments (r = 0.56; P<0.01). Serum TSH (H =
5.29; P = 0.15), IL-2 (H = 4.94; P = 0.17) and
gIFN (H = 2.84; P = 0.41) levels were similar
in all four hyperthyroid groups, but serum
IL-2 (Z = 5.27; P<0.001) and gIFN (Z = 5.25;
P<0.001) levels were higher in hyperthyroid
patients than in the control group.
There was no significant difference in
serum IL-2 levels between GD patients and
control subjects (Z = 0.18; P = 0.42) but GD
patients had significantly lower gIFN levels
(Z = 2.16; P = 0.01). Serum IL-2 and gIFN
levels were similar in treated and untreated
GD patients (Z = 0.75; P = 0.22 for IL-2 and
Z = 1.36; P = 0.08 for gIFN).
Comparison of GD patients (group I)
with groups II, III and IV (non-autoimmune
hyperthyroid patients) showed that group I
presented higher serum IL-2 levels (Z = 1.74;
P = 0.04) but similar serum gIFN levels (Z =
0.34; P = 0.36). Non-autoimmune hyperthy-
roid patients also showed lower serum IL-2
and gIFN levels than the control subjects (Z
= 4.62; P<0.001 and Z = 4.49; P<0.001,
respectively). The 3 non-autoimmune hy-
perthyroid patient subgroups had similar se-
rum IL-2 and gIFN levels (H = 2.89; P = 0.23
and H = 0.46; P = 0.79, respectively).
The pattern of cytokine expression within
a diseased tissue and serum cytokine profile
can provide important information about
pathogenesis. In GD, where thyroid hyper-
function induced by stimulating antibodies
predominates over tissue destruction, a TH2
dominance would be expected. Also, it would
be reasonable to predict higher cytokine lev-
els in Graves disease than in nodular goiters
or other primarily non-autoimmune diseases.
However, literature data are difficult to in-
terpret. Besides methodological caveats,
there are many factors interfering with im-
mune regulation of humans, like counter-
regulatory cytokines and the effect of drugs.
As also observed in some other autoimmune
diseases, some serum cytokines may serve
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as disease activity markers in GD (7,8). In
particular, a form of the a chain of IL-2,
called soluble IL-2 receptor, seems to in-
crease in response to T3 stimulation, corre-
lating positively with serum thyroid hor-
mone concentrations (7,8,12).
In the present study, we evaluated the
serum concentration of IL-2 and gIFN levels
in hyperthyroid patients, comparing 21 GD,
untreated and on thionamide therapy, with
19 patients with non-autoimmune hyperthy-
roid diseases. We found lower levels of se-
rum IL-2 and gIFN in the hyperthyroid pa-
tients than in the control subjects (P<0.01),
suggesting that hyperthyroidism induces a
depressed TH1 pattern. This is possibly one
more evidence of the direct effect of thyroid
hormone levels over human lymphocytes in
vivo independent of the etiology of the hy-
perthyroidism (8,13). There was a signifi-
cant elevation in hyperthyroid patient mean
IL-2 serum levels compared to normal indi-
viduals (P<0.001). This cytokine could come
from the thyroid gland. Watson et al. (2),
using the reverse transcription-polymerase
chain reaction (RT-PCR), demonstrated that
a wide variety of cytokines are produced by
infiltrating mononuclear cells and by folli-
cular cells in GD, in contrast to the poor
cytokine production observed in multinodu-
lar goitrous patients. Thionamide treatment
of GD patients could have been a bias in our
data, interfering with the expression of cyto-
kines, but we found no difference between
treated and non-treated patients (14).
In conclusion, we found major differ-
ences in serum IL-2 levels between GD and
other hyperthyroid states. More data, such as
the quantification of serum IL-4 and IL-10
levels in both GD and non-autoimmune hy-
perthyroid patients are necessary in order to
clarify the role of cytokines. However, this
easily measurable cytokine could be of help
in the not infrequent situation in which clini-
cal evaluation and laboratory data are insuf-
ficient to distinguish GD from other hyper-
thyroid states.
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